We thank the following national societies and patient organisations who have already endorsed the campaign.

NATIONAL SOCIETIES & PATIENT GROUPS

Visit www.CallAllergyAsthma.eu to see the current list of endorsers from around the world.

Visit a political call to action

SHOW YOUR SUPPORT AND ENDORSE TODAY

Endorsing is simple and quick, taking no longer than 5 minutes

Please visit www.CallAllergyAsthma.eu

Click on your relevant group and fill out the short form

Spread the word amongst friends and colleagues using #CallAllergyAsthma

Together we stand united to create a healthier and happier future for the over 220 million allergy and asthma patients in Europe

A heart felt thank you for your support!

Visit www.CallAllergyAsthma.eu to see the current list of endorsers from around the world.
As members of the European Parliament, healthcare professionals and patients, we call out to you

Today, there is still no cure for allergy and asthma, and large discrepancies in monitoring, prevention, early diagnosis, treatment and care exist across Europe. Strong and united European political leadership is urgently needed to successfully curb this dramatic epidemic for the benefit of our patients, economies and society.

WE CALL UPON EU MEMBER STATES TO:

• Unify or define new national chronic disease policies to include allergy and asthma
• Define national allergy and asthma programmes built on evidence-based, successful, preventive and tolerance-inducing approaches
• Invest in allergy and asthma prevention and early detection, including awareness campaigns and training programmes for healthcare professionals
• Dedicate national public funding to allergy and asthma research and generate evidence to further informing tailored national policies
• Encourage placing allergy and asthma as a health priority in the agenda of the upcoming EU Council Presidencies

WE CALL UPON THE EUROPEAN COMMISSION TO:

• Place allergy and asthma at the forefront of EU chronic disease action
• Encourage coordinated European and national policy responses on allergy and asthma with a health systems approach
• Land coordination support to collect public health indicators and monitor trends on allergy and asthma
• Promote and support financially via the EU Health Programme, the exchange and dissemination of good practices and programmes among Member States
• Promote and support financially via horizon 2020 and future programmes, scientific research to address underlying triggers and develop innovative treatments to care allergy and asthma
• Encourage greater cooperation and coordination between Member States for the promotion of allergy and asthma programmes

WE CALL UPON MEMBERS OF THE EUROPEAN PARLIAMENT TO:

• Support this Call to Action and its pan European advocacy campaign
• Raise awareness among EU and Member States policy-makers
• Encourage the development of coordinated European strategies to foster allergy and asthma programmes
• Prioritize addressing allergy and asthma in EU and national health and environmental policies
• Fight against disease triggers, many of which are common to all chronic diseases, by fostering supportive legislation at EU level on indoor and outdoor air quality (food safety, (chemicals)

WE CALL UPON CIVIL SOCIETY, PARTICULARLY PATIENTS, HEALTHCARE PROFESSIONALS AND HEALTH ADVOCATES TO:

• Endure and relay the Call to Action. Engage in joint advocacy of EU and national levels to improve awareness, monitoring, prevention and management of allergy and asthma across Europe
• Engage in dialogue with national governments and EU institutions to share knowledge, expertise and strategic advice to shape sound policies and successfully act on allergy and asthma in Europe
• Promote personalised allergy and asthma medicine and contribute to shifting European healthcare systems towards person-centred and outcome-based models, that benefit patients, economies and societies

The current burden of allergy and asthma on our society

Allergy and asthma are among the most frequent chronic diseases in the European Union (EU). Over 100 million EU citizens are affected. More than 100 million Europeans have asthma, around 100 million live with allergic rhinitis, and 17 million with a food allergy. By 2025, it is estimated that one-half of the entire EU population will be affected by these diseases.

Allergy and asthma severely impact the quality of life of patients, with dramatic effects on their professional and educational performance. A considerable number of allergic patients (15-20%), live with a severely debilitating disease and under fear of death from a possible allergy attack or anaphylactic shock.

In addition to the detriment to individuals, allergy and asthma challenge the sustainability of our healthcare systems, in terms of direct and indirect costs. The total spend on asthma alone in Europe is estimated at €22 billion per year, while the latest scientific evidence review, conducted by GALLEN (Global Allergy and Asthma European Network of Excellence), estimates that absenteeism due to insufficiently treated allergy costs between €35-150 billion per year across the EU. Appropriate treatment would cost only 5% of this sum, allowing savings of up to €24 billion.

The EP Interest Group on Allergy and Asthma is a common effort by European allergy and asthma patients, health professionals and Members of the European Parliament (MEPs) committed to address what likely constitutes the most prevalent chronic diseases in Europe. The prevalence of allergy and asthma has increased in alarming proportions in the past decades in conjunction with rising environmental challenges, such as pollution and climate change.

The European Academy of Allergy and Clinical Immunology (EAACI) is a non-profit association including over 11,000 academicians, research investigators and clinicians from 121 different countries.

The European Federation of Allergy and Airways Diseases Patients’ Associations (EFA) is the European Federation of Allergy and Airways Diseases Patients’ Associations (EFA) is the European Federation of Allergy and Airways Diseases Patients’ Associations. The European Federation of Allergy and Airways Diseases Patients’ Associations (EFA) is a non-profit association including over 11,000 academicians, research investigators and clinicians from 121 different countries.

The European Academy of Allergy and Clinical Immunology (EAACI) is a non-profit association including over 11,000 academicians, research investigators and clinicians from 121 different countries.

The European Federation of Allergy and Airways Diseases Patients’ Associations (EFA) is the European Federation of Allergy and Airways Diseases Patients’ Associations (EFA) is a non-profit association including over 11,000 academicians, research investigators and clinicians from 121 different countries.